Literature DB >> 16092089

Alpha-synuclein dysfunction in Lewy body diseases.

George K Tofaris1, Maria Grazia Spillantini.   

Abstract

alpha-Synuclein belongs to a small group of natively unfolded proteins that can transiently bind to lipid membranes and acquire a partial alpha-helical conformation. Its relevance to Parkinson's disease (PD) is based on mutations found in familial cases of the disease and its presence in filaments of Lewy bodies (LB) and Lewy neurites (LN) in sporadic cases where it is packed in a beta-sheet configuration. This structural plasticity of alpha-synuclein has raised the possibility that neurodegeneration may be a consequence of abnormal protein folding. The extent to which abnormal folding and aggregation of neuronal proteins is directly toxic to the cell, an inert biochemical marker of an underlying harmful metabolic defect, or a protective reaction remains to be seen. We review the function of alpha-synuclein and recent studies that have shed light on the mechanisms by which it aggregates. Copyright 2005 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16092089     DOI: 10.1002/mds.20538

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  24 in total

1.  Whole genome expression profile in neuroblastoma cells exposed to 1-methyl-4-phenylpyridine.

Authors:  E Mazzio; K F A Soliman
Journal:  Neurotoxicology       Date:  2012-07-07       Impact factor: 4.294

2.  Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson's disease.

Authors:  Kateri J Spinelli; Jonathan K Taylor; Valerie R Osterberg; Madeline J Churchill; Eden Pollock; Cynthia Moore; Charles K Meshul; Vivek K Unni
Journal:  J Neurosci       Date:  2014-02-05       Impact factor: 6.167

Review 3.  Genetic animal models of Parkinson's disease.

Authors:  Ted M Dawson; Han Seok Ko; Valina L Dawson
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

Review 4.  Chaperones and proteases: cellular fold-controlling factors of proteins in neurodegenerative diseases and aging.

Authors:  Marie-Pierre Hinault; Anat Ben-Zvi; Pierre Goloubinoff
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 5.  New Therapeutic Strategies for Lewy Body Dementias.

Authors:  Latha Velayudhan; Dominic Ffytche; Clive Ballard; Dag Aarsland
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

6.  Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with alpha-synuclein genotype.

Authors:  Irit Rappley; David S Myers; Stephen B Milne; Pavlina T Ivanova; Matthew J Lavoie; H Alex Brown; Dennis J Selkoe
Journal:  J Neurochem       Date:  2009-07-17       Impact factor: 5.372

Review 7.  Formation and development of Lewy pathology: a critical update.

Authors:  Kurt A Jellinger
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

Review 8.  Heat shock protein 90: the cancer chaperone.

Authors:  Len Neckers
Journal:  J Biosci       Date:  2007-04       Impact factor: 1.826

9.  Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy.

Authors:  Margot Fournier; Jérémie Vitte; Jérôme Garrigue; Dominique Langui; Jean-Philippe Dullin; Françoise Saurini; Naïma Hanoun; Fernando Perez-Diaz; Fabien Cornilleau; Chantal Joubert; Héctor Ardila-Osorio; Sabine Traver; René Duchateau; Cécile Goujet-Zalc; Katerina Paleologou; Hilal A Lashuel; Christian Haass; Charles Duyckaerts; Charles Cohen-Salmon; Philipp J Kahle; Michel Hamon; Alexis Brice; Olga Corti
Journal:  PLoS One       Date:  2009-08-14       Impact factor: 3.240

10.  Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease.

Authors:  Bo Su; Haihua Liu; Xinglong Wang; Shu G Chen; Sandra L Siedlak; Eisaku Kondo; Raymond Choi; Atsushi Takeda; Rudy J Castellani; George Perry; Mark A Smith; Xiongwei Zhu; Hyoung-Gon Lee
Journal:  Mol Neurodegener       Date:  2009-07-23       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.